Self-Admin Delivery Terrestrial's adhesive MAP patch enables self-administration of therapies without refrigeration or sharps, presenting a compelling value proposition for partnering with patient-centric delivery programs, home healthcare providers, and direct-to-consumer channels seeking convenient, low-risk administration options.

Therapy Pipeline Fit With proven concept across multiple molecules and a platform designed for a wide range of therapeutics, target opportunities include partnerships with biotech and pharma companies pursuing next-generation biologics, vaccines, or hormones seeking improved stability and patient adherence.

Global Expansion Readiness The technology’s temperature-stable, scalable format supports distribution in remote or emerging markets with limited cold chain, opening opportunities for collaboration with regional distributors, contract manufacturers, and global health initiatives focused on accessible delivery technologies.

Clinical Proof Momentum Strong clinical and in-vivo proof across molecules suggests potential for co-development or licensing deals with companies seeking to de-risk early-stage therapies by adopting preclinical-to-clinical-ready delivery platforms and accelerated regulatory pathways.

Strategic Partnerships Given the emphasis on self-administered, stable delivery and a growing field of digital and data-enabled healthcare, explore alliances with patient support programs, telemedicine platforms, and digital health companies to integrate MAP-based therapies into comprehensive care ecosystems.